BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Eluri S, Brugge WR, Daglilar ES, Jackson SA, Styn MA, Callenberg KM, Welch DC, Barr TM, Duits LC, Bergman JJ. The Presence of Genetic Mutations at Key Loci Predicts Progression to Esophageal Adenocarcinoma in Barrett's Esophagus. Am J Gastroenterol. 2015;110:828-834. [PMID: 26010308 DOI: 10.1038/ajg.2015.152] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Kalatskaya I. Overview of major molecular alterations during progression from Barrett's esophagus to esophageal adenocarcinoma. Ann N Y Acad Sci 2016;1381:74-91. [PMID: 27415609 DOI: 10.1111/nyas.13134] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
2 Critchley-Thorne RJ, Davison JM, Prichard JW, Reese LM, Zhang Y, Repa K, Li J, Diehl DL, Jhala NC, Ginsberg GG, DeMarshall M, Foxwell T, Jobe BA, Zaidi AH, Duits LC, Bergman JJ, Rustgi A, Falk GW. A Tissue Systems Pathology Test Detects Abnormalities Associated with Prevalent High-Grade Dysplasia and Esophageal Cancer in Barrett's Esophagus. Cancer Epidemiol Biomarkers Prev 2017;26:240-8. [PMID: 27729357 DOI: 10.1158/1055-9965.EPI-16-0640] [Cited by in Crossref: 19] [Cited by in F6Publishing: 10] [Article Influence: 3.2] [Reference Citation Analysis]
3 Soh YSA, Lee YY, Gotoda T, Sharma P, Ho KY;  Asian Barrett's Consortium. Challenges to diagnostic standardization of Barrett's esophagus in Asia. Dig Endosc. 2019;31:609-618. [PMID: 30892742 DOI: 10.1111/den.13402] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
4 Brown CS, Lapin B, Goldstein JL, Linn JG, Talamonti MS, Carbray J, Ujiki MB. Predicting Progression in Barrett's Esophagus: Development and Validation of the Barrett's Esophagus Assessment of Risk Score (BEAR Score). Annals of Surgery 2018;267:716-20. [DOI: 10.1097/sla.0000000000002179] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
5 Critchley-Thorne RJ, Duits LC, Prichard JW, Davison JM, Jobe BA, Campbell BB, Zhang Y, Repa KA, Reese LM, Li J, Diehl DL, Jhala NC, Ginsberg G, DeMarshall M, Foxwell T, Zaidi AH, Lansing Taylor D, Rustgi AK, Bergman JJ, Falk GW. A Tissue Systems Pathology Assay for High-Risk Barrett's Esophagus. Cancer Epidemiol Biomarkers Prev. 2016;25:958-968. [PMID: 27197290 DOI: 10.1158/1055-9965.epi-15-1164] [Cited by in Crossref: 24] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
6 Gregson EM, Bornschein J, Fitzgerald RC. Genetic progression of Barrett's oesophagus to oesophageal adenocarcinoma. Br J Cancer 2016;115:403-10. [PMID: 27441494 DOI: 10.1038/bjc.2016.219] [Cited by in F6Publishing: 32] [Reference Citation Analysis]
7 Trindade AJ, Navaneethan U, Aslanian HR, Bhutani MS, Krishnan K, Lichtenstein DR, Melson J, Pannala R, Parsi MA, Schulman AR, Sethi A, Trikudanathan G, Watson RR, Maple JT. Advances in the diagnosis and surveillance of Barrett’s esophagus (with videos). Gastrointestinal Endoscopy 2019;90:325-34. [DOI: 10.1016/j.gie.2019.05.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
8 Das A, Callenberg KM, Styn MA, Jackson SA. Endoscopic ablation is a cost-effective cancer preventative therapy in patients with Barrett's esophagus who have elevated genomic instability. Endosc Int Open 2016;4:E549-59. [PMID: 27227114 DOI: 10.1055/s-0042-103415] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
9 Naini BV, Souza RF, Odze RD. Barrett's Esophagus: A Comprehensive and Contemporary Review for Pathologists. Am J Surg Pathol. 2016;40:e45-e66. [PMID: 26813745 DOI: 10.1097/pas.0000000000000598] [Cited by in Crossref: 54] [Cited by in F6Publishing: 25] [Article Influence: 9.0] [Reference Citation Analysis]
10 Cook MB, Thrift AP. Epidemiology of Barrett's Esophagus and Esophageal Adenocarcinoma: Implications for Screening and Surveillance. Gastrointest Endosc Clin N Am 2021;31:1-26. [PMID: 33213789 DOI: 10.1016/j.giec.2020.08.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
11 Redston M, Noffsinger A, Kim A, Akarca FG, Rara M, Stapleton D, Nowden L, Lash R, Bass AJ, Stachler MD. Abnormal TP53 predicts risk of progression in patients with Barrett's esophagus regardless of a diagnosis of dysplasia. Gastroenterology 2021:S0016-5085(21)03710-0. [PMID: 34757142 DOI: 10.1053/j.gastro.2021.10.038] [Reference Citation Analysis]
12 Konda VJA, Souza RF. Biomarkers of Barrett's Esophagus: From the Laboratory to Clinical Practice. Dig Dis Sci. 2018;63:2070-2080. [PMID: 29713984 DOI: 10.1007/s10620-018-5088-2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
13 Konda VJA, Souza RF. Barrett’s Esophagus and Esophageal Carcinoma: Can Biomarkers Guide Clinical Practice? Curr Gastroenterol Rep 2019;21. [DOI: 10.1007/s11894-019-0685-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
14 Souza RF, Spechler SJ. Advances in Biomarkers for Risk Stratification in Barrett's Esophagus. Gastrointest Endosc Clin N Am 2021;31:105-15. [PMID: 33213790 DOI: 10.1016/j.giec.2020.08.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
15 Hui YY, Chen X, Wang BM. Yesterday and today of Barrett's esophagus: Historical evolution and research hotspots. Shijie Huaren Xiaohua Zazhi 2016; 24(20): 3077-3086 [DOI: 10.11569/wcjd.v24.i20.3077] [Reference Citation Analysis]
16 Eluri S, Klaver E, Duits LC, Jackson SA, Bergman JJ, Shaheen NJ. Validation of a biomarker panel in Barrett's esophagus to predict progression to esophageal adenocarcinoma. Dis Esophagus 2018;31. [PMID: 29635420 DOI: 10.1093/dote/doy026] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
17 Abbas G, Krasna M. Overview of esophageal cancer. Ann Cardiothorac Surg. 2017;6:131-136. [PMID: 28447001 DOI: 10.21037/acs.2017.03.03] [Cited by in Crossref: 56] [Cited by in F6Publishing: 54] [Article Influence: 11.2] [Reference Citation Analysis]
18 Stachler MD, Camarda ND, Deitrick C, Kim A, Agoston AT, Odze RD, Hornick JL, Nag A, Thorner AR, Ducar M, Noffsinger A, Lash RH, Redston M, Carter SL, Davison JM, Bass AJ. Detection of Mutations in Barrett's Esophagus Before Progression to High-Grade Dysplasia or Adenocarcinoma. Gastroenterology 2018;155:156-67. [PMID: 29608884 DOI: 10.1053/j.gastro.2018.03.047] [Cited by in Crossref: 54] [Cited by in F6Publishing: 46] [Article Influence: 13.5] [Reference Citation Analysis]
19 Trindade AJ, McKinley MJ, Alshelleh M, Levi G, Stewart M, Quinn KJ, Thomas RM. Mutational load may predict risk of progression in patients with Barrett's oesophagus and indefinite for dysplasia: a pilot study. BMJ Open Gastroenterol 2019;6:e000268. [PMID: 30815274 DOI: 10.1136/bmjgast-2018-000268] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
20 Dunbar KB, Souza RF. Beyond Dysplasia Grade: The Role of Biomarkers in Stratifying Risk. Gastrointest Endosc Clin N Am 2017;27:447-59. [PMID: 28577766 DOI: 10.1016/j.giec.2017.02.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
21 Craig MP, Rajakaruna S, Paliy O, Sajjad M, Madhavan S, Reddy N, Zhang J, Bottomley M, Agrawal S, Kadakia MP. Differential MicroRNA Signatures in the Pathogenesis of Barrett's Esophagus. Clin Transl Gastroenterol 2020;11:e00125. [PMID: 31934893 DOI: 10.14309/ctg.0000000000000125] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]